'If you do not expect the unexpected you will not find it, for it is not to be reached by search or trail. ' Heraclitus
Background
There are already many links between hemostasis and innate immunity, which have a strong connection in terms of a common evolutionary ancestry as immediate responses to injury. In addition to the commonalities between coagulation and inflammation, fibrin clots play an important role in host antimicrobial defense. Strong evidence comes from research using mice lacking fibrinogen or with a mutant form of fibrinogen that cannot form fibrin, with the consequence of impaired bacterial clearance and decreased survival after infection with certain bacteria [1] . Fibrin networks act as a physical barrier to bacterial invasion. Also, some immune and inflammatory cells, such as neutrophils, are activated by binding to fibrin(ogen). Conversely, some bacteria have evolved the ability to bind specifically to fibrin to evade the immune system by forming resistant bacterial biofilms. The recent report of fibrin biofilms at the liquid-air interface of fibrin clots provides another mechanism for antimicrobial protection [2] . Although the discovery of these fibrin biofilms may appear unexpected, their existence on the surface of in vitro clots has been known for quite some time. Since we worked out methods for preparing samples and started doing scanning electron microcopy of clots, we have seen these fibrin films for nearly 35 years. However, during all that time, we regarded these films as an artifact of surface drying because this phenomenon could be ameliorated by formation of clots in a humid chamber. During this time, as we taught many other scientists how to prepare clots for scanning electron microscopy, they all also observed such films. Thus, the real breakthrough here is not the observation, but the insight that these films could have some biological significance. Indeed, because such films are difficult to prevent in vitro, in retrospect it seems likely that they would occur in vivo at liquid-air interfaces, but this possibility had never been considered and studied previously.
On a very superficial level, these fibrin films might be suspected to have some structural similarities to the ultrathin fibrin sheets formed over channels that were described about 10 years ago [3] . However, these fibrin sheets occur under quite different circumstances. They polymerize on hydrophobic or hydrophilic surfaces, usually at very low fibrinogen and thrombin concentrations. They are molecularly thin and extensive, but can fold and roll up into fibers. The main mechanistic similarity is that both the fibrin biofilms and the ultra-thin fibrin sheets are formed as a result of physical association of fibrin(ogen) molecules distinct from the classical half-staggered polymerization.
Key findings of this paper
Fibrin and fibrinogen form a thin film at the liquid-air interface during the process of clot formation [2] . Rather than being a typical porous network of fibers, these films appear to be made up of tightly packed molecules arranged perpendicular to the liquid-air interface tethered to the underlining polymeric fibrin network. The films can be made of uncleaved fibrinogen without fibrin, although they form slowly in this case, and they can be digested by plasmin formed in the presence of tissue-type plasminogen activator, which typically is responsible for fibrinolysis of fibrin clots. The thickness of the film depends on multiple physical and biological conditions, such as thrombin activity, calcium ion concentration, fibrinogen concentration, fibrinogen polymorphisms and mutations (dysfibrinogenemias), temperature, etc. The films have been characterized by scanning electron microcopy from both sides, the interior and exterior surfaces, which differ in smoothness and porosity. To reproduce the physical mechanism of the film formation, the generation of a monolayer of fibrinogen and fibrin and a liquidair interface was studied using a Langmuir-Blodgett trough, an instrument that measures surface pressure of the liquid phase, followed by calculation of the molecular dimensions of the monolayer. Using confocal microscopy, the formation of fibrin biofilm was studied as a function of time. Fibrin accumulates at the surface at a much faster rate than fibrinogen. The strength of the fibrin biofilm was characterized with atomic force microscopy in different areas of the structure and in the presence and absence of factor XIIIa activity, which stabilizes the film by covalent crosslinking. Formation of the film is prevented by surfactants or any covering of the liquid-air interface. The film helps to retain blood cells inside a clot, because it is relatively impermeable. More importantly, it prevents or delays bacterial infiltration in vitro and bacterial proliferation on the surface of a blood clot formed in mice at the site of dermal injury.
Novel ideas
This work describes the formation of protein lamina at a phase boundary that confines blood clots both structurally and functionally. Langmuir film formation, which has been known for a long time, is a phenomenon occurring with most or all proteins in solution. However, here an important biological function is proposed for this film. In a general context, the work by Macrae et al. [2] studies a molecular mechanism of spatial biological partitioning that may occur without formation of phospholipid membranes, perhaps similarly to assembly of some membrane-less cellular organelles. Irrespective of the underlying mechanisms, formation of a proteinaceous film surrounding a blood clot can be considered as an example of biological compartmentalization, a structural and functional biological principle now applied to the extracellular matrix.
Biological plausibility
The proposed effects of fibrin biofilms at a wound surface, as a temporary seal, as part of hemostasis and/or a protective means against bacteria appear most plausible. In Boyden chamber experiments, the fibrin biofilms prevent the passage of bacteria. In the mouse wound model, the authors of this paper measured proliferation of bacteria but not passage across the fibrin biofilm. It would be worthwhile for future studies to look for bacterial infiltration, in addition to the studies in this paper on proliferation. This could be done, for example, by making histological sections perpendicular to the wound surface, to look for bacteria that are below the fibrin biofilm.
This paper presents fibrin biofilms as a barrier in wounds exposed to the air, for which it is most directly applicable in vivo. The next obvious question is whether such films might occur in intravascular clots or thrombi.
In fact, there is in the literature some evidence for fibrin being on the surface of intravascular clots [4] . However, one model of hemostasis in the mouse cremaster muscle blood vessels shows a tightly packed core of highly activated platelets at the site of injury and more loosely packed, less activated platelets in the shell, with most fibrin under the core at the site of injury and in the extravascular space [5] . More studies need to be carried out to investigate the presence of fibrin biofilms intravascularly in other models and in clinical settings.
The structure and composition of human arterial and venous thrombi have been examined by scanning electron microscopy [6] . Interestingly, the exterior of parts of some thrombi have some apparent similarity to the fibrin biofilms described in this paper. We know from in vitro studies of clot contraction (retraction) that the surface appearance of such thrombi arises from the redistribution of fibrin and platelets to the surface and red blood cells to the interior during the process of clot contraction. Thus, the concentration of fibrin(ogen) at the liquid-air boundary in these fibrin biofilms is seemingly similar, but is very different in nature from redistribution of fibrin and platelets towards the surface during platelet-driven contraction of clots and thrombi. Such surface accumulation of fibrin has been observed both in in vitro blood clots and ex vivo thrombi and considered a morphological marker of intravital contraction of intravascular thrombotic masses [6] . There is still a likelihood that the film-like coating often observed in scanning electron micrographs of ex vivo thrombi in some cases may comprise an artifact of sample preparation (e.g. a densified layer of unwashed plasma proteins crosslinked by the glutaraldehyde used as a fixative).
With the naming of these structures in fibrin biofilms, there is some potential confusion of terminology. These films should not be confused with 'fibrin films' made by John Ferry many years ago by compression of fibrin clots and used as sealants for wounds. In addition, there is much research on biofilms, which most commonly refers to colonies of bacteria that form a layer on many surfaces, so this fibrin biofilm is clearly quite different. Bacterial biofilms are much thicker and are made up of a complex ecosystem of bacteria and supporting players. On the other hand, there is a gleeful irony to this terminology, in that these fibrin biofilms seem to protect against bacteria, rather than being composed of bacteria in a form resistant to most means of antibacterial attack.
Strengths of this paper
The suggestions for a biological purpose of fibrin biofilms and the accompanying experiments are quite novel. The authors looked at a commonly occurring observation in vitro and realized it may have biological significance. They also carried out a thorough characterization and provided both in vitro and in vivo evidence for the presence of such fibrin biofilms and the conditions of their formation.
Unanswered questions
The most significant questions are how widespread are such fibrin films, and how important are they biologically and clinically? Are such films present in intravascular clots or thrombi? Is a liquid-air interface required or can they be formed at a liquid-solid interface (as suggested by one paper cited by the authors)? Do they aid in hemostasis? Where they are present, do these films have the potential to limit clot growth?
More information is needed about the structure of the biofilms, because the conclusions on structure here are somewhat tentative. For example, the orientation of the molecules in the surface layer was deduced from the protein density, and not yet demonstrated with structural approaches. Are other plasma proteins also involved in film formation? If so, what is the relative contribution of fibrin (ogen) and these other proteins? If the film is a monolayer of fibrinogen and/or fibrin molecules, does the width of the adjacent fibrin fibers affect the properties of the biofilm? Because thrombin is not necessary for formation of the biofilm, and fibrinogen slowly forms weak films, can the Langmuir phenomenon be inherently associated with blood clotting? Are the weaker fibrinogen films different in structure to the stronger fibrin biofilms? Can the film properties be affected by the presence of platelets, because the film formation depends strongly on thrombin activity, which would be enhanced by platelets?
How different is a skin wound from intravascular blood clotting in terms of physical interaction with air vs. vessel wall, and the existence of non-biological mechanisms of formation of the biofilm? Can reduced bacterial proliferation associated with the presence of the biofilm be explained by physical attachment of bacteria to the surface? Is reduced bacterial proliferation in a skin wound model fully equivalent to protection from microbial invasion?
Likely impact of this paper and future perspectives
In the most optimistic scenario, these fibrin biofilms could be a major new form of polymeric fibrin(ogen) that is prevalent in nature and has broad biological significance. However, it remains to be determined how general this fibrin biofilm formation is in hemostasis and thrombosis. In any case, it is clear that additional research is needed.
Conclusions
This paper presents evidence for a novel function of a different structural form of fibrin(ogen) that appears as another connection between the innate immune system and blood clotting. These biofilms can act as barriers to bacterial invasion in dermal wounds. Surface fibrin biofilms would be more effective than three-dimensional fibrin clots at controlling infection at sites of injury, which is consistent with the known problems with cutaneous infections in afibrinogenemic patients, although other aspects of fibrin's role in infection must also be taken into account [1] . Evidence for any more extensive roles of fibrin biofilms in hemostatic or immune functions awaits further research. One conclusion is sure: fibrin is a remarkable biological object with continual new surprises.
